TY  - GEN
N2  - Opioid Use Disorder (OUD) is an ongoing epidemic that effects millions of individuals worldwide. There is limited research on OUD in patients with cancer and standardized screening for OUD is largely no utilized in the oncology setting, although a high percentage of cancer patients will receive an opioid prescription during oncology treatment. This study aimed to address this gap by implementing the Opioid Risk Tool- Revised (ORT-R) in oncology clinics to assess the scope of high-risk individuals among this population. The ORT-R, a validated screening tool, was introduced to providers and administered to new oncology patients at four Oregon Health and Science University (OHSU) Knight Cancer Institute clinics. Data collection occurred over three months, assessing completion rates and identifying high-risk individuals. Implementation strategies involved staff training sessions, emphasizing the importance of OUD screening, and integrating the ORT-R into routine new patient paperwork. Among 149 oncology patients completing the ORT-R, 13.42% screened high risk for developing OUD. The results align with existing literature, supporting the efficacy of using the ORT-R in oncology settings, and reinforcing the need for standardized screening for OUD in oncology patients. 
AB  - Opioid Use Disorder (OUD) is an ongoing epidemic that effects millions of individuals worldwide. There is limited research on OUD in patients with cancer and standardized screening for OUD is largely no utilized in the oncology setting, although a high percentage of cancer patients will receive an opioid prescription during oncology treatment. This study aimed to address this gap by implementing the Opioid Risk Tool- Revised (ORT-R) in oncology clinics to assess the scope of high-risk individuals among this population. The ORT-R, a validated screening tool, was introduced to providers and administered to new oncology patients at four Oregon Health and Science University (OHSU) Knight Cancer Institute clinics. Data collection occurred over three months, assessing completion rates and identifying high-risk individuals. Implementation strategies involved staff training sessions, emphasizing the importance of OUD screening, and integrating the ORT-R into routine new patient paperwork. Among 149 oncology patients completing the ORT-R, 13.42% screened high risk for developing OUD. The results align with existing literature, supporting the efficacy of using the ORT-R in oncology settings, and reinforcing the need for standardized screening for OUD in oncology patients. 
AD  - Oregon Health and Science University
T1  - Screening for risk of opioid use disorder in patients with cancer 
DA  - 2024-04-08
AU  - Monda, Alisa
L1  - https://digitalcollections.ohsu.edu/record/42857/files/Monda.Alisa.2024.pdf
PB  - Oregon Health and Science University
LA  - eng
PY  - 2024-04-08
ID  - 42857
L4  - https://digitalcollections.ohsu.edu/record/42857/files/Monda.Alisa.2024.pdf
KW  - Opioid-Related Disorders
KW  - Oncology Nursing
KW  - Analgesics, Opioid
KW  - Early Detection of Cancer
KW  - cancer
KW  - neoplasms
TI  - Screening for risk of opioid use disorder in patients with cancer 
Y1  - 2024-04-08
L2  - https://digitalcollections.ohsu.edu/record/42857/files/Monda.Alisa.2024.pdf
LK  - https://digitalcollections.ohsu.edu/record/42857/files/Monda.Alisa.2024.pdf
UR  - https://digitalcollections.ohsu.edu/record/42857/files/Monda.Alisa.2024.pdf
ER  -